• In late April 2026, Illumina reported first-quarter results showing revenue of US$1.09 billion and net income of US$134 million, alongside higher earnings per share and an increased full-year 2026 revenue outlook of US$4.52–US$4.62 billion.
• At the same time, the Board authorized a new US$1.5 billion share repurchase program on top of buybacks already reducing the share count by more than 7%, underscoring management’s confidence in the company’s financial position and demand trends.
• With Illumina raising 2026 guidance following stronger-than-expected Q1 results, we’ll examine how this could reshape the existing investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Illumina Investment Narrative Recap

To own Illumina, you need to believe that clinical sequencing and multiomics can support steady, recurring growth even as research and China remain uneven. The main short term catalyst is continued clinical uptake of platforms like NovaSeq X, while the biggest risk is that research funding softness and export restrictions weigh on instrument demand. The latest Q1 beat and modest guidance raise support the clinical story but do not fully resolve those demand and geopolitical concerns.

The announcement that stands out most here is the new US$1.5 billion share repurchase authorization, on top of buybacks that have already reduced the share count by more than 7%. This move sits alongside higher 2026 revenue guidance of US$4.52–US$4.62 billion and stronger Q1 margins, reinforcing the role of capital returns and cost discipline as supporting catalysts if Illumina can sustain clinical growth and execution on its multiomics roadmap.

Yet behind these positives, investors should be aware of how rising competition and regulatory scrutiny could still pressure...

Illumina's narrative projects $5.0 billion revenue and $1.0 billion earnings by 2029. This requires 5.1% yearly revenue growth and about a $150 million earnings increase from $850.0 million today.

Uncover how Illumina's forecasts yield a $136.11 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest target analysts were assuming revenue of about US$5.0 billion and earnings of roughly US$982 million by 2029, so compared with the recent guidance upgrade and stronger Q1 print, their view reflects a much more cautious stance on Illumina’s long term upside and reminds you that reasonable investors can look at the same numbers and reach very different conclusions.

Explore 4 other fair value estimates on Illumina - why the stock might be worth as much as 15% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Illumina research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.